Aura, Claudia - Search Results - UAB Digital Repository of Documents

Search collections:

Sort by:	Display results:	Output format:

UAB Digital Repository of Documents	2 records found	Search took 0.01 seconds.

12 p, 5.0 MB

Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies / Vicario, Rocío (Vall d'Hebron Institut d'Oncologia) ; Peg, Vicente (Hospital Universitari Vall d'Hebron) ; Morancho, Beatriz (Vall d'Hebron Institut d'Oncologia) ; Zacarías-Fluck, Mariano F (Vall d'Hebron Institut d'Oncologia) ; Zhang, Junjie (Vall d'Hebron Institut d'Oncologia) ; Martínez-Barriocanal, Águeda (Vall d'Hebron Institut d'Oncologia) ; Navarro Jiménez, Alexandra (Hospital Universitari Vall d'Hebron) ; Aura, Claudia (Vall d'Hebron Institut d'Oncologia) ; Burgués, Octavio (Hospital Clínic Universitari (València)) ; Lluch, Ana (Hospital Clínic Universitari (València)) ; Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ; Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ; Rubio, Isabel T. (Vall d'Hebron Institut d'Oncologia) ; Marangoni, Elisabetta (Institut Curie) ; Deeds, James (Novartis Oncology Translational Research (Estats Units d'Amèrica)) ; Boehm, Markus (Novartis Pharma AG (Suïssa)) ; Schlegel, Robert (Novartis Oncology Translational Research (Estats Units d'Amèrica)) ; Boehm, Markus (Novartis Pharma AG (Suïssa)) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Mosher, Rebecca (Novartis Oncology Translational Research (Estats Units d'Amèrica)) ; Boehm, Markus (Novartis Pharma (Suïssa)) ; Arribas, Joaquín V (Institució Catalana de Recerca i Estudis Avançats) ; Universitat Autònoma de Barcelona
A chromosomal region that includes the gene encoding HER2, a receptor tyrosine kinase (RTK), is amplified in 20% of breast cancers. Although these tumors tend to respond to drugs directed against HER2, they frequently become resistant and resume their malignant progression. [...]
2015 - DOI (Digital Object Identifier)

10.1371/journal.pone.0129876
PloS one, Vol. 10 (june 2015)

Detailed record -

10 p, 1.9 MB

High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy / Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ; Thyparambil, Sheeno (OncoPlex Diagnostics. USA) ; Aura, Claudia (Vall d'Hebron Institut d'Oncologia) ; Garrido-Castro, Ana (Hospital Universitari Vall d'Hebron) ; Vilaro, Marta (Vall d'Hebron Institut d'Oncologia) ; Peg, Vicente (Hospital Universitari Vall d'Hebron) ; Jimenez, José (Vall d'Hebron Institut d'Oncologia) ; Vicario, Rocío (Vall d'Hebron Institut d'Oncologia) ; Cecchi, Fabiola (OncoPlex Diagnostics. USA) ; Hoos, William (OncoPlex Diagnostics. USA) ; Burrows, Jon (OncoPlex Diagnostics. USA) ; Hembrough, Todd (OncoPlex Diagnostics. USA) ; Ferreres Piñas, Joan Carles (Hospital Universitari Vall d'Hebron) ; Pérez-Garcia, José (Hospital Universitari Vall d'Hebron) ; Arribas, Joaquín V. (Vicente) (Institució Catalana de Recerca i Estudis Avançats) ; Cortés, Javier (Hospital Universitari Vall d'Hebron) ; Scaltriti, Maurizio (Memorial Sloan Kettering Cancer Center) ; Universitat Autònoma de Barcelona
Introduction: Current methods to determine HER2 (human epidermal growth factor receptor 2) status are affected by reproducibility issues and do not reliably predict benefit from anti-HER2 therapy. Quantitative measurement of HER2 may more accurately identify breast cancer (BC) patients who will respond to anti-HER2 treatments. [...]
2016 - DOI (Digital Object Identifier)

10.1016/j.molonc.2015.09.002
Molecular Oncology, Vol. 10, núm 1 (January 2016) , p. 138-147

Detailed record -

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.